An interventional study of intensive toe pressure evaluation and data collection in Critical Limb Ischemia (CLI), sponsored by University Hospital, Bordeaux. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Chronic Limb-Threatening Ischemia with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · France.
Among the 22 studies in Chronic Limb-Threatening Ischemia with a site in France, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2025, is one of 3 with no phase, and was the 20th registered.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
Browse Chronic Limb-Threatening Ischemia studies →7 of the 22 studies in Chronic Limb-Threatening Ischemia with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 18+
Centre Hospitalier le Mans · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Fondation Hôpital Saint-Joseph · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 40+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 4
First in 2007; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 200 is above the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.
Median enrollment 50 across the 11 interventional studies, 300 across the 11 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 2 studies filed under Chronic Limb-Threatening Ischemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Limb-Threatening Ischemia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238050University Hospital, AngersNOrmoBaric Oxygen Therapy Use In Critical Limb ISchemia | 2026-12 |
| NCT07014072University Hospital, BordeauxComprehensive Limb Evaluation and Arterial Revascularization With Toe Pressure Optimization Registry | 2027-07-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Chronic Limb-Threatening Ischemia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To address the heterogeneity of practices, better understand the outcomes of cricital limb theatening ischemia (CLTI) patients after endovascular interventions, and recognize effective endovascular options for infrapopliteal artery revascularization in CLTI, our prospective registry aims to tackle the critical question of whether intensive toe pressure evaluation, guiding repeat revascularization using predetermined thresholds (\<30 mmHg or decrease >10% from immediate postoperative assessment), could optimize outcomes in patients with CLTI.
Cricital limb theatening ischemia (CLTI) represents the most advanced stage of peripheral arterial disease (PAD), leading to high mortality rates and limb loss. A primary endovascular strategy is now preferred for most patients with CLTI who have occlusive disease of the tibial arteries. This is especially true for the elderly, diabetic patients, and those without suitable venous conduits for bypass. Patients with CLTI and infra-popliteal occlusive disease do not always respond well to the provided treatment, but the underlying reasons, particularly in those showing good initial results after endovascular revascularization, remain to be determined.
The literature strongly supports the use of drug-eluting stents (DES) in treating infrapopliteal arteries. DES are associated with significant improvements in patency, reduced rates of restenosis and reintervention, and better Rutherford-Becker classification and healing of trophic disorders. However, contrary to initial expectations, the SAVAL trial, whose data were made public in December 2023, comparing a DES dedicated to infra-popliteal arteries with percutaneous transluminal angioplasty in patients with CLTI, failed to meet its primary efficacy (increased primary patency and reduced major adverse events rate) and safety objectives at 12 months, despite preliminary data suggesting an advantage in using DES for treating short lesions. A possible explanation is the significant heterogeneity of practices, with less than half of the patients receiving optimal medical treatment and intensive follow-up, highlighting the need for a comprehensive review of treatment strategies in this challenging patient population.
The lack of an established objective follow-up protocol for this patient group underscores the need for innovative approaches. Currently, there is no widely available consensus indicator to estimate whether the revascularization provided will be sufficient to prevent amputation. The Delta-Perf study has completed its recruitment and is expected to provide results on foot perfusion analysis in patients with CLTI before and after revascularization and its predictive value on amputation-free survival. However, despite high initial technical success rates for endovascular interventions, early failure of these minimally invasive procedures is common.
Current recommendations support duplex scan monitoring and prophylactic reintervention for asymptomatic graft stenosis to promote long-term patency, but monitoring and reintervention strategies after endovascular management have been left to the practitioner's discretion. There are no ongoing studies to determine if the initial improvement observed in the foot is actually maintained, and there is little evidence to support indications for repeated interventions in CLTI. Clinical follow-up alone may be insufficient to detect restenosis, as patients may remain asymptomatic until the target artery is occluded, similar to venous grafts in bypasses. Likewise, measuring the ankle-brachial index (ABI) alone has limited value, given the difficulty in determining the level of restenosis, technical limitations in diabetic patients with calcified vessels, and variability in correlation with the severity of lesions.
It is likely that there are subgroups of patients who could benefit more than others from early reintervention. Toe pressure, in this context, offers a measurable, non-invasive, and clinically relevant parameter that can be consistently evaluated even in challenging cases, particularly in heavily calcified patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 patients with CLTI treated in the past 3 years at the same center. Patients in this cohort were treated according to standard clinical practices at the time, without intensive toe pressure evaluation to guide reinterventions, and with reinterventions guided solely by clinical criteria.
Other: data collection
100 patients included prospectively and treated as part of the study. Patients in this cohort will be followed with an intensive toe pressure evaluation approach (TcPO2), guiding reinterventions according to predetermined thresholds (\<30 mmHg or decrease \>10% from immediate postoperative assessment). This cohort will receive best medical treatment:
Procedure: intensive toe pressure evaluation
This measurement is non-invasive, painless and is also carried out as part of the care in the follow-up of critical limb ischemia. It takes place like a blood pressure measurement except that it is carried out at the level of a toe.
retrospective data
Toe pressure with Systolic pressure measurement device
The Systolic pressure measurement device is suitable for the toes, as part of the diagnosis or monitoring of obliterating arteriopathy of the lower limbs, as for the fingers of the hand during assessments relating to arteriovenous fistulas. The Systolic pressure measurement device ingeniously uses photoplethysmography (PPG) associated with a unique algorithm developed and patented by Atys Medical. PPG makes it possible to detect, thanks to a photoelectric cell (sensor), variations in blood flow in skin traffic. The Systolic pressure measurement deviceputs the measurement of digital pressure pressure within the reach of all the stakeholders concerned (angiologists, nephrologists, diabetologists, vascular surgeons, wound and healing services, etc.).
Time frame: Day 15, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Evaluation of Survival
Describe if patient is alive or not
Time frame: Day 15, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Evaluation of the absence of target lesion occlusion.
Evaluation of absence of occlusion of the target lesion by Echo-doppler
Time frame: Day 15, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Evaluation of target lesion revascularization
Evaluation of target lesion revascularization using Echo doppler
Time frame: Day 15, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Evaluation of major adverse limb events
Evaluation of major amputation or major reinterventions including new bypass surgery, bypass revision, or thrombectomy/thrombolysis related to the target lesion
Time frame: Day 15, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Evaluation ofthe Wound healing with WiFi classification
It takes into account the patient's foot wound, ischemia and infection. This system can be used to determine the estimated 1-year risk of amputation and the estimated probability of benefit/need for revascularization. It is a useful, standardized tool that can help determine patient risk and the need for intervention.
Time frame: Day 15, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Evaluation of the Wound healing with colorimetry scale
Colorimetry involves analyzing the different colors present in a wound to determine its condition and stage of healing. Each color corresponds to a specific tissue or biological process.
Time frame: Day 15, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Plan to share: Yes — The data is available from Pr DUACSSE. An email can be sent to her so that she can contact the data manager and owner, the Bordeaux University Hospital. The data can be made available after contractual agreement
Supporting information: Study protocol, Informed consent form
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Jul 2027, 24 months later.
Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Limb-Threatening Ischemia →
University Hospital, Bordeaux →